Izvorni znanstveni članak
Hemovigilance and post-transfusion reactions to blood components in patients with solid tumors
Miroslav Banović
; Department of Transfusiology and Hemostasis, University Hospital for Tumors, Zagreb, Croatia
Marija Lovrić
; University Hospital for Tumors, Zagreb, Croatia
Irena Veliki-Dalić
; Department of Pathology, University Hospital for Tumors, Zagreb, Croatia
Miro Banović
; School of Medicine, University of Rijeka, Rijeka, Croatia
Sažetak
Hemovigilance is a system of surveillance and alarm in transfusion activities from blood donor selection to the followup of the blood component recipients, gathering and analyzing all untoward effects of blood transfusion in order to correct their cause and prevent recurrence. A 5-year surveillance (2005-2009) showed the overall consumption of 6790 unit doses (1358/year): erythroconcentrate (EC) 973.4 ± 71, platelet concentrate (PC) 216 ± 66.93, fresh frozen plasma (FFP)122.4 ± 59.05 and cryoprecipitate (CP) 46.2 ± 26.63. During the five years, there were 38 adverse events (22 non-hemolytic febrile transfusion reactions (NHFTR), 16 allergic reactions (AR), or an average annual rate of 7.6 reactions ( 4.4 NHFTR, 3.2 AR). Neither serious adverse events nor death was reported. EC caused 0.043% of NHFTR (risk 1:2,326) and 0.015% of AR (risk 1:3,125), while FFP lead to 0.18% of NHFTR (risk 1:556) and 1.18% of AR (risk 1:85). No reaction to PC and CP was reported. The annual rate for 10,119 blood components (EC,PC, FFP,CP) was 0.043% of NHFTR (risk 1:2,326), and 0.032% of AR (risk 1:3,125). Our results are within the range of worldwide standards.
Ključne riječi
hemovigilance; red blood cells; post-transfusion reaction
Hrčak ID:
278704
URI
Datum izdavanja:
30.11.2009.
Posjeta: 403 *